Where do I go from Yale - Panelist Bios

Panel on Corporate & Research - BIOGRAPHIES

James Burton (Ph.D. 1970, Molecular Biophysics & Biochemistry) grew up on the Navajo reservation outside of Shiprock, New Mexico. He graduated from Texas Tech University in chemistry and, as a graduate student at Yale, completed the first semi-synthesis of a protein. Subsequently he did postdoctoral research in Oxford on new methods for the chemical synthesis of peptides. He then joined the staff at the Massachusetts General Hospital/Harvard Medical School where he designed and tested the first renin inhibitor that was active in vivo. At Boston University Medical Center he developed the first specific inhibitor of tissue kallikrein and the first inhibitors of the IgA proteases produced by pathogenic bacteria. During his academic career Dr. Burton was principal investigator on about $8M in NIH grants, served on numerous study sections, and consulted widely in the pharmaceutical industry. In 1990 family illness caused Dr. Burton to leave research and found RSP Amino Acid Analogues - a company dedicated to the manufacture of a series of amino acids for use in drug design. In 2005 he founded Psyche Pharmaceuticals to develop methods for the chemical synthesis of single domain antibodies for use as drugs.

Clay Dean (M.A. 2000, Renaissance Studies and History of Art) worked in various entry-level roles in the financial sector. He eventually became a portfolio manager at a small asset management company and later transitioned to commercial banking. He currently serves as a senior manager at a small regional bank in Illinois where he is in charge of commercial and private banking and business development.

Charlie Liu (Ph.D. 1988, Physics), after a postdoc at Argonne National Laboratory, joined AT&T Bell Laboratories in 1991 to begin a career in the telecommunication industry. Among his contributions at AT&T, he led a cross process team to establish the feasibility, impact assessment, and the benefit of introducing SONET gears into the AT&T transport network. The work transformed AT&T’s old DS3 network into the modern OC-N and DWDM transport network to meet ever-increasing demand. He is currently working at Comcast and leading IPv6 implementation/design of its converged regional area networks.  He has three US patents, with two more in process.

Sheenah Mische (Ph.D. 1988, Experimental Pathology) is senior director of the Office of Collaborative Science and associate professor of pathology at New York University Langone Medical Center.  She is responsible for the oversight and promotion of state-of-the-art technology resources for the research community.  Sheenah has broad experience in the operation and administration of multi-technology, multidisciplinary resource centers in support of institutional research missions, both in academia and in industry.  In her most recent positions, she was director of translational sciences, and director of protein resources at Boehringer Ingelheim Pharmaceuticals.  She also served as associate director for Talent Acquisition and Academic Relations for Boehringer Ingelheim, Prior to that she was director of the Protein / DNA Technology Center at Rockefeller University. 

R. Nagarajan
(Ph.D. 1988, Engineering & Applied Science) is currently a professor in the Department of Chemical Engineering at the Indian Institute of Technology Madras, India. Prior to taking up this academic position in 2004, Dr. Nagarajan was a world-renowned expert in the areas of chemical integration and contamination control during his 15-year tenure with IBM Storage Systems Division (SSD) in San Jose, CA.  Dr. Nagarajan was designated as an IBM Technical Resource in 2002, one among very few in North America. He has co-authored a book on “Contamination and ESD Control in High-Technology Manufacturing,” published by J Wiley & Sons in September 2006.  His current areas of research include ultrasonic process intensification and nano-technology.

Rahul Prasad
(Ph.D. 1987, Engineering & Applied Science) presently works for the Lawrence Livermore National Laboratory in California. He heads a group that designs x-ray diagnostics for the National Ignition Facility. In the years after he received his PhD, he has also been on the research faculty at Yale, worked as a research scientist, first in large company (Physics International), then a small business (Science Research Lab) and co-founded a small business (Alameda Applied Sciences Corporation) in 1994.

Petra Scamborova (Ph.D. 2005, Molecular Biophysics and Biochemistry) currently works as an associate in the litigation department of Paul, Hastings, Janofsky and Walker LLP in New York City.  She focuses her work on patent litigation in the pharmaceutical and biotechnology areas.  She has been a member of several trial teams involved in biologics as well as Hatch-Waxman litigations.   As she was finishing her PhD, Dr. Scamborova started attending the University of Pennsylvania Law School from which she graduated in 2006.